Clinical Trials on Kidney Impairment

Total 15388 results

UCB Pharma
Parexel

Completed

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

Healthy Subjects | Renal Impairments

Japan
Yuhan Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Healthy Volunteer | Renal Impairments

Korea, Republic of
Eisai Inc.

Completed

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Hepatic Impairment; Renal Impairment

United States
AstraZeneca

Completed

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Renal Impairment | Hepatic Impairment

Bulgaria
JW Pharmaceutical

Completed

A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment

Healthy, Renal Impairment

Korea, Republic of
Kowa Research Institute, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

Severe Renal Impairment

United States
Gilead Sciences

Terminated

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Severe Renal Impairment

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Melbourne Health

Withdrawn

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Renal Impairment After Cardiac Surgery

Australia
Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
Conatus Pharmaceuticals Inc.

Completed

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

Kidney Diseases | Renal Insufficiency | Renal Impairment | Kidney Disease

United States
Genfit

Completed

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Kidney Diseases | Renal Insufficiency | Renal Impairment | Pharmacokinetics

France, Romania
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

Renal Impairment | Hepatic Impairment

China
Takeda

Completed

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Renal Impairment | Hepatic Impairment

Japan
Universidad Europea de Madrid

Completed

Effectiveness of a Program Based on Observation-action Training (AOT) in Patients With Cognitive Impairment.

Cognitive Impairments

Spain
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Renal Impairment | Kidney Disease | Renal Disease

United States
VA Office of Research and Development

Completed

Video-Enhanced Care Management for Medically Complex Veterans

Multimorbidity | Cognitive Impairments

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Affiliated Hospital of Zhengzhou University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Chronic Renal Impairment

China
University of Novi Sad, Faculty of Sport and Physical...

Completed

Molecular Hydrogen for Cognitive Function and Performance in Elderly

Aging | Cognitive Impairments

Serbia
Amgen

Completed

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Renal Impairment

United States
Amgen

Completed

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Renal Impairment | Advanced Solid Tumors | Kidney Disease

United States
Allecra

Completed

Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects

PK in Patients With Various Degrees of Renal Impairment

Czechia, Hungary
Novartis Pharmaceuticals

Completed

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Mild Moderate | or Severe Renal Impairment

Germany
Centre Hospitalier Universitaire de Saint Etienne
GlaxoSmithKline

Completed

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. (PROPICE)

Major Orthopaedic Surgery and Renal Impairment

France
Janssen-Cilag International NV

Terminated

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Kidney Failure, Chronic

Germany
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Renal Impairment

United States
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants

Renal Impairment

United States, Germany
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Renal Impairment

United States
BioVersys AG
CRU Hungary Kft; CRU Hungary Early Phase Unit

Completed

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Renal Impairment

Hungary
Haisco Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

Renal Impairment

China
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Arthrosi Therapeutics
Iqvia Pty Ltd

Completed

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Renal Impairment

United States, New Zealand
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment

United States, Romania
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Renal Impairment

Germany
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Renal Impairment

United States
The Medicines Company

Completed

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Renal Impairment

New Zealand
Wockhardt
Clinartis

Completed

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

Renal Impairment

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Renal Impairment

United States
Wockhardt
Clinartis

Completed

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Renal Impairment

United States
Polyphor Ltd.

Completed

Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment

Renal Impairment

Germany
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Renal Impairment Study

Renal Impairment

Czech Republic, Hungary
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Renal Impairment

Canada

3

Subscribe